DelveInsight’s ‘Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Soft Tissue Sarcoma (STS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market The Soft Tissue Sarcoma market report provides analysis regarding current treatment practices, emerging drugs like AL3818, Fibromun, AL3818, Ripretinib, market share of the individual therapies, historical, current and forecasted Soft Tissue Sarcoma market Size from 2017 to 2030 segmented by seven major markets.

1. Soft Tissue Sarcoma
Market Insight, Epidemiology and Market Forecast - 2030

2. Private and Confidential
Introduction to DelveInsight
To help organizations make important business
decisions through the use and analysis of
actionable market intelligence. It is our mission to
provide the most effective results and services
coupled with acute client care to create a long-
lasting relationship with our clients.
Mission
To become the most trusted marketing research &
business consulting firm worldwide.
To be a renowned and premier data driven solution
providers among Pharma & Biotech companies.
Vision
Actionable
Intelligence
Shaping & Influencing
the Strategic Thinking
Accurate market
assessment of competitors,
products & technology
provides DelveInsight
insightful valuation of
industry evolution. Understanding
Industry
Evolution
Industry
Experience
In-depth knowledge of
Healthcare Industry with
focus on Pharmaceutical
and Biotechnological
Domain.
Discovering liabilities for a
more robust intelligence
output, uncovering possible
reasons for strategic failure,
and work to avoid them.
Blind spot
Analysis
Dedicated
Monitoring
Focused on current players
tracking, as well as on
monitoring new entrants for
forecasting their impact on
the market. Emphasis is on
checking for any disruptive
substitute in the market.

3. Lorem Ipsum is simply dummy text of the printing and typesetting industry.
Lorem Ipsum has been the industry's standard dummy text ever since the
1500s.
KPI DashboardYour great subtitle in this line
Lorem ipsum dolor sit
amet, consectetur
Drink Coffee
Lorem ipsum dolor sit
amet, consectetur
Mobile Data
Lorem ipsum dolor sit
amet, consectetur
Love
Overview of pathophysiology, various
diagnostic approaches and treatment
algorithm including detailed chapters for
marketed products and emerging therapies
Detailed historical and forecasted
market covering the United States,
EU5, and Japan from 2017 to 2030
Pipeline analysis across different stages of
development (Phase III and Phase II),
different emerging trends and comparative
analysis of pipeline products with detailed
clinical profiles, key cross -competition,
launch date along with product development
activities.
Detailed Market size by therapies,
covering the United States, EU5
(Germany, France, Italy, Spain, and
United Kingdom), and Japan from
2017 to 2030
Historical as well as forecasted epidemiology
in 7MM covering the United States, EU5
(Germany, France, Italy, Spain, and United
Kingdom), and Japan from 2017 to 2030
Research
Analysis
Market
Analysis
Pipeline
Valuation
Market Size by
Therapies
Epidem
Forecast
Soft Tissue Sarcoma

4. A detailed review of Soft Tissue Sarcoma
market; historical and forecasted is
included in the report, covering drug
outreach in the 7MM
Comprehensive insight has been provided
into the Soft Tissue Sarcoma epidemiology
and treatment in the 7MM
The report covers the descriptive overview
of Soft Tissue Sarcoma, explaining its
causes, signs and symptoms,
pathophysiology and currently available
therapies
Additionally, an all-inclusive account of both
the current and emerging therapies for Soft
Tissue Sarcoma are provided, along with the
assessment of new therapies, which will have
an impact on the current treatment landscape
4
The report provides an edge while developing
business strategies, by understanding trends
shaping and driving the global Soft Tissue
Sarcoma market
Scope Of Report

5. D
D
Soft Tissue Sarcoma - Introduction
• Soft-tissue sarcoma (STS) are rare neoplasms that can develop in supporting or
connective tissue, such as the muscle, nerves, tendons, blood vessels and fatty
and fibrous tissues. They commonly affect the arms, legs, and trunk. They also
appear in the stomach and intestines (GIST) as well as behind the abdomen
(retroperitoneal sarcomas) and the female reproductive system (gynecological
sarcomas).
• STSs may be classified according to the involved cell-type, the specific nature
of the malignancy, and the disease’s clinical course. According to the World
Health Organization (WHO), there are more than 50 histologic subtypes of
STSs.
• The signs and symptoms of STSs vary greatly from patients to patients based on
the type of STS. However, it is not associated with any noticeable symptoms
early in the course of the disease but the affected individuals may notice slow-
growing, painless mass in the affected area.
• Many STSs associated with reciprocal translocations. Some forms of STS are
associated with a variation (mutation) in a single oncogene, which is believed to
drive the growth of cancer. An altered (mutation) oncogene may produce a
protein that is ineffective, overproduced, or under-produced. Environmental
factors that have been associated with STSs include radiation therapy and
exposure to certain chemicals, including vinyl chloride, arsenic, and thorium
dioxide.

6. 6
Soft Tissue Sarcoma
Epidemiology Insight

7. 55+ Years
21-54 Year
<20
Age-Specific Incidence of STS in the US
0 1000 2000 3000 4000 5000 6000 7000 8000
Localized Type
Regional Type
Distant Type
Other Type
Stage-Specific Incidence of STS in the US
Stage-Specific Incidence of STS in the US
According to DelveInsight’s analysts, in the US, localized
stage accounted for 60% of overall STS cases in 2017. In
2017, there were 7,434 cases of localized type, 2,354 cases of
regional type, 1,859 cases of regional type, and 743 cases of
unknown type.
Stage-Specific Incidence of STS in the US
For DelveInsight’s epidemiology model, different age-groups
are included: <20 years, 21–54 years, and 55 plus years. It is
estimated that the most incident age-group for STS in the US
was 55+ years in 2017. Patients of age groups 21–54 years
were observed to be the second-highest, in 2017.

8. 8
Soft Tissue Sarcoma
Market Insight
11 Years
Forecast
7MM
Coverage
Epidemiology
Segmentation
Key Cross
Competition
Highly
Analyzed
Market
Drugs
Uptake

9. Lorem Ipsum is simply dummy text of
the printing and typesetting industry.
9
6.47%CAGR
Soft Tissue Sarcoma Market Size
is Expected to Increase With a
Soft Tissue Sarcoma Market
XX XX XX
US Germany France
XX
Italy
XX XX XX
Spain UK Japan
MARKET SHARE SEGMENTATION OF 7MM COUNTRIES IN 2030

10. Lorem Ipsum is simply dummy text of
the printing and typesetting industry.
10
Soft Tissue Sarcoma Market
172.52
182.56
188.81
195.29
201.87
208.25
182.17
158.66
138.15
119.88
103.96
89.22
76.96
65.80
48.68 51.54 53.31 55.16 57.02 58.77 60.68 62.7 63.58 64.47 65.32 66.01 67.1 68.23
10.72 11.29 11.64 12.01 12.37 12.67 13.02 13.35 13.71 14.05 14.35 14.56 14.9 15.2311.07 11.33 11.36 11.39 11.34 11.26 11.24 11.17 11.11 10.98 10.74 10.36 10.14 9.83
1.82 1.84 1.84 1.83 1.81 1.79 1.81 1.81 1.81 1.8 1.78 1.74 1.71 1.684.25 4.33 4.34 4.35 4.34 4.31 4.33 4.33 4.33 4.31 4.27 4.19 4.15 4.091.57 1.61 1.61 1.61 1.6 1.58 1.6 1.61 1.63 1.64 1.64 1.63 1.62 1.613.43 3.54 3.57 3.6 3.59 3.57 3.5 3.42 3.34 3.22 3.05 2.8 2.65 2.453.68 3.8 3.82 3.84 3.83 3.78 3.77 3.7 3.63 3.53 3.36 3.11 2.95 2.770.35 0.35 0.35 0.35 0.35 0.35 0.34 0.34 0.33 0.32 0.3 0.27 0.26 0.231.05 1.08 1.09 1.1 1.1 1.09 1.07 1.03 0.99 0.94 0.86 0.76 0.69 0.60.25 0.26 0.26 0.26 0.26 0.26 0.26 0.26 0.26 0.25 0.25 0.23 0.22 0.211.25 1.29 1.29 1.29 1.28 1.27 1.29 1.29 1.3 1.3 1.29 1.26 1.25 1.220.06 0.06 0.06 0.06 0.06 0.06 0.06 0.05 0.05 0.04 0.03 0.02 0.01 0.010.03 0.03 0.03 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.040.21 0.21 0.21 0.22 0.22 0.21 0.21 0.19 0.18 0.16 0.14 0.1 0.08 0.060.49 0.51 0.51 0.52 0.52 0.51 0.51 0.5 0.49 0.48 0.46 0.43 0.42 0.39
246.67
260.51
268.94
277.68
286.43
294.74
270.89
249.59
230.17
212.9
197.73
183.25
172.05
161.84
0 0 0 0 0 0 1.84 2.74 4.08 6.07 9.05
13.48 13.83 17.17
0 0 0 0 0
15.93
22.24
31.05
43.34
60.51
84.48
117.95 121.33 124.77
0 0 0 0 3.68 5.9 9.45
15.15 15.14 15.13 15.12 15.11 15.76 16.6
0 0 0 0
5.1 6.89
18.68
25.35
34.39
46.67
63.33
85.94
100.2
119.52
0 0 0 0 0 0 0 0 2 2.89 4.18 6.03 8.72 12.59
0 0 0 0 0 0 0 0 0 3.58 5.18 7.48 10.8
15.6
0 0 0 0 0 0 0 3.91 5.65 8.16 11.79
17.03
24.61 24.84
0 0 0 0 0 0 0
5.33 7.44 10.39 14.51
20.26
28.28
39.49
0 0 0 0 0 0 0 0 3.28 4.74 6.85 9.9
14.29
20.65
0 0 0 0 0 0 0 0.76 1.14 1.73 2.6 3.93 3.93 3.930.00
50.00
100.00
150.00
200.00
250.00
300.00
350.00
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
USDMillion
Market Size of STS by therapies
Votrient Yondelis Halaven
Anthracycline Regimens other doxorubicin-based regimens doxorubicin, ifosfamide
doxorubicin liposomal doxorubicin Non-anthracycline regimens
ifosfamide-based regimens docetaxel gemcitabine
gemcitabine, docetaxel ifosfamide gemcitabine, decarbazine
paclitaxel other Total Current Revenue of STS (1L+2L+3L+4L)
Vigil AL3818 Selinexor
Fibromun GSK 3377794 Tazemetostat
Abemaciclib Pembrolizumab Crizotinib
ABI-009

11. 11
Soft Tissue Sarcoma
Emerging Therapies

12. Lorem Ipsum is simply dummy text of
the printing and typesetting industry.
12
Emerging Therapies
Avapritinib
Anlotinib
Selinexor
Ripretinib
Crenolanib
Fibromun
GSK3377794
Companies CompaniesDrugs Drugs

13. Market Drivers & Barrier
Market Driver
Market Barrier
Competitive Landscape
Precision Medicine Approach
Novel Therapies for Subtype of STS
High Cost of Treatment
Stringent Government Regulations
High Failure Rate in the Clinical Trials

14. KOL Opinion Analysis
Rare Disease Segment has scarcity of data through published literature, with statistical analysis also having dearth of information.
DelveInsight surpasses this challenge through its extensive Primary Research, through its association with Key Opinion Leaders across the
Globe
R&D Assessment
KOLs include Research
Scientists, Clinical Trial
Investigators, Research Nurses,
General Practitioners, Medical
Consultants, as well as Specialty
Physicians
Epidemiology Assessment
KOLs include Epidemiologists, Company
Personnel, Disease Organizations’ Executives,
Medical Consultants, Consulting analysts, as
well as Specialty Physicians etc.
Market Assessment
KOLs include Financial Analysts,
Freelance Consultants, Company
Personnel, B Consulting analysts,
as well as Specialty Physicians
etc.

15. DelveInsight KOL Network
DelveInsight has an extensive KOL Network, from in-house experts to associated personnel, across all geographies, who provide accurate
and real time insights on the research needs of DelveInsight’s clients
Our Extensive Coverage of the
Healthcare Industry can be assessed
from our reach across the Global
Markets
Our External panel consists of our
associations with Key Opinion Leaders on
Project basis, where we recruit key personnel
related to the therapy area/disease area in
question to assess thoughts on the Industry
Trends
Our internal panel consists of Dr. BK
Agrawal and his associations of
Pharma Consultants, Medical
Doctors and Industry Leaders

16. Pricing & Reimbursement

17. Related Reports
"Soft Tissue Sarcoma Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of
present clinical development scenario and growth prospects across the Soft Tissue Sarcoma market. A
detailed picture of the Soft Tissue Sarcoma pipeline landscape is provided, which includes the disease
overview and Soft Tissue Sarcoma treatment guidelines.
 Soft Tissue Sarcoma - Pipeline Insights, 2020
 Soft Tissue Sarcoma - Epidemiology Forecast to 2030
DelveInsight's 'Soft Tissue Sarcoma - Epidemiology Forecast to 2030' report delivers an in-depth
understanding of the disease, historical and forecasted Soft Tissue Sarcoma epidemiology in the 7MM, i.e.,
the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

18. Contact Us
+91-11-45689769
+1(919)-321-6187
info@delveinsight.com Click Here Click Here
Click Here to visit our Report Store

19. Thank You